ZEISS and Mindpeak Partner to Revolutionize Pathology with AI-Driven Multiplex Immunofluorescence Solution

ZEISS and Mindpeak Partner to Revolutionize Pathology with AI-Driven Multiplex Immunofluorescence Solution

(IN BRIEF) ZEISS Research Microscopy Solutions and AI pathology leader Mindpeak have joined forces to develop an integrated Multiplex Immunofluorescence (mIF) solution. Combining ZEISS’ advanced imaging technologies with Mindpeak’s AI-driven pathology algorithms, the solution targets research, diagnostics, and clinical applications. It simplifies workflows from slide preparation to reporting, supporting personalized medicine and daily pathological assessments. The collaboration aims to meet the growing demand for reproducible mIF workflows, advancing insights and precision in pathology. The joint solution will debut at the European Society for Molecular Biomarkers (ESSB) Conference in Berlin, December 2024.

(PRESS RELEASE) JENA, 12-Dec-2024 — /EuropaWire/ — ZEISS Research Microscopy Solutions has partnered with Mindpeak, a leader in AI-powered pathology, to develop a comprehensive Multiplex Immunofluorescence (mIF) solution designed to address the diverse needs of pathologists in research, diagnostics, and clinical applications. This collaboration combines the strengths of ZEISS’ advanced microscopy and imaging technologies with Mindpeak’s innovative AI-based pathology algorithms.

Bridging Research and Clinical Applications

The joint mIF solution aims to support key market segments, including:

• Research: Providing cutting-edge tools for advanced scientific investigations.
• Diagnostics (Dx) and Companion Diagnostics (CDx): Accelerating personalized medicine initiatives.
• Clinical Routine: Offering reliable and efficient AI-powered tools for daily pathological assessments.

Mindpeak’s proven expertise in AI-driven analysis of immunohistochemistry (IHC) and hematoxylin and eosin (H&E) stained slides will now extend to mIF. This integration creates a streamlined workflow that simplifies the process from slide preparation to analytical reporting.

“Mindpeak’s clinical AI algorithms have already transformed pathological workflows in routine diagnostics. By partnering with ZEISS, we can bring our expertise in AI pathology to the realm of mIF, delivering powerful, integrated solutions that enhance efficiency and precision for our users,” said Felix Faber, CEO of Mindpeak.

Advancing Pathology Workflows

Michael Albiez, Head of ZEISS Research Microscopy Solutions, emphasized the significance of the collaboration: “ZEISS is dedicated to driving innovation that bridges the gap between research and clinical applications. Partnering with Mindpeak represents a milestone in advancing workflows for both translational research and clinical pathology. By combining ZEISS’ imaging capabilities with Mindpeak’s AI analytics, we are enabling deeper insights and improved reproducibility across mIF workflows.”

The integrated solution addresses the growing demand for efficient and reproducible mIF workflows in pathology, providing researchers and clinicians with tools to gain more accurate insights. The partnership seeks to expand both companies’ reach in the rapidly evolving mIF market.

First Public Showcase

ZEISS and Mindpeak will present their joint mIF solution for the first time at the European Society for Molecular Biomarkers (ESSB) Conference in Berlin on December 12-13, 2024. Attendees will have the opportunity to explore the system’s potential and learn more about its capabilities. Additional updates will follow as the platform development progresses.

This collaboration underscores the commitment of both ZEISS and Mindpeak to enhancing the capabilities of pathologists, ensuring that they have access to cutting-edge tools for research, diagnostics, and clinical applications.

About Mindpeak

Founded in 2018, Mindpeak is a global innovator in AI-driven digital pathology solutions. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results. Mindpeak’s platform is designed to enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes in cancer care. For more information, visit mindpeak.ai, X, and LinkedIn.

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023).

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world’s leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company’s significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS’ technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With over 44,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, 35 research and development facilities, and 35 production facilities worldwide (status: 31 March 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

ZEISS Research Microscopy Solutions

ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.

Further information at www.zeiss.com/microscopy

Media Contacts:

Vybhav Sinha
ZEISS Research Microscopy Solutions
tel:+49 (0)3641 64 3949
press.microscopy@zeiss.com

Katja Eisele
Mindpeak GmbH
tel:+49 40 35 67 67 97
katja.eisele@mindpeak.ai

SOURCE: ZEISS